Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03064438
Other study ID # ACU-D1
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 28, 2017
Est. completion date June 18, 2018

Study information

Verified date August 2021
Source Accuitis, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 18, 2018
Est. primary completion date June 5, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant is male or non-pregnant and non-lactating female at least 18 years of age - Participant has a clinical diagnosis of stable papulopustular rosacea (type-2) - Participant has a total of =10 and =40 inflammatory lesions (papules, pustules, and nodules) on the face - Participant has =2 nodules on the face - Participant has an investigator's global assessment (IGA) score of =3 - If the participant is a woman of childbearing potential, she has a negative urine pregnancy test and agrees to use an approved effective method of birth control for the duration of the study - Participant is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of rosacea or which exposes the participant to an unacceptable risk by study participation - Participant is willing and able to follow all study instructions and to attend all study visits - Participant is able to comprehend and willing to sign an informed consent form Exclusion Criteria: - Participant is pregnant, nursing, or planning to become pregnant during the duration of the study - Participant has used systemic glucocorticosteroids within 42 days prior to Visit 1 (inhaled and ocular glucocorticosteroids are permitted) - Participant has used systemic antibiotics within 28 days prior to Visit 1 - Participant has used any topical glucocorticosteroids on the face within 28 days prior to Visit 1 - Participant has used any prescription or over-the-counter product for the treatment of acne or rosacea within 14 days prior to Visit 1 - Participant is currently using any therapy that, in the investigator's opinion, is a photosensitizer (for example, phenothiazines, amiodarone, quinine, thiazides, sulphonamides, quinolones, etc.) - Participant currently has any skin disease (for example, psoriasis, atopic dermatitis, eczema), or condition (for example, actinic keratosis, photo-damage, sunburn, excessive hair, open wounds) that, in the investigator's opinion, might impair evaluation of rosacea or which exposes the subject to an unacceptable risk by study participation - Participant currently has, on the face, or has had on the face, any of the following within the specified period prior to Visit 1 that, in the investigator's opinion, might impair evaluation of rosacea or which exposes the subject to an unacceptable risk by study participation: - A cutaneous malignancy; 180 days - Experienced a sunburn; 14 days - Participant has facial hair, that in the investigator's opinion, might impair evaluation of rosacea or proper study medication application - Participant has a history of sensitivity to any of the ingredients in the study medications - Participant has participated in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to Visit 1

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ACCU-D1
ACCU-D1
Vehicle
Placebo Comparator

Locations

Country Name City State
United States DermResearch Austin Texas
United States DS Research Louisville Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Accuitis, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Week 12 Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.
Score 0 (clear): no erythema present
Score 1 (mild): slight erythema
Score 2 (moderate): definite erythema
Score 3 (severe): marked, fiery erythema
Week 12
Other Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Day 1 (Post-application) and Weeks 2, 4, 8, and 14 Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.
Score 0 (clear): no erythema present
Score 1 (mild): slight erythema
Score 2 (moderate): definite erythema
Score 3 (severe): marked, fiery erythema
Day 1 (Post-application) and Weeks 2, 4, 8, and 14
Primary Change From Baseline in Total Lesion Count at Week 12 Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, <0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, <0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass =0.5 cm in diameter. Baseline, Week 12
Secondary Percent Change From Baseline in Investigator's Global Assessment (IGA) Score at Weeks 2, 4, 8, and 12 The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema
Score 1 (near clear): very few (=3) papules and/or pustules, no nodules, very mild erythema
Score 2 (mild): few papules and pustules present, no nodules, mild erythema
Score 3 (moderate): several papules and pustules are the predominant features, =2 nodules may be present, moderate erythema
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema
Baseline; Weeks 2, 4, 8, and 12
Secondary Percentage of Participants Who Were Treatment Responders at Week 12 Treatment responders were defined as participants who have either (1) 2 ordinal or more reductions in the IGA score from baseline or (2) an IGA score of 0 or 1.
The IGA score is an ordered categorical value ranging from 0 (clear) to 4 (severe). A lower score indicated improvement in the condition.
Score 0 (clear): no papules or pustules, no nodules, none or barely perceptible erythema
Score 1 (near clear): very few (=3) papules and/or pustules, no nodules, very mild erythema
Score 2 (mild): few papules and pustules present, no nodules, mild erythema
Score 3 (moderate): several papules and pustules are the predominant features, =2 nodules may be present, moderate erythema
Score 4 (severe): numerous papules and pustules, multiple nodules may be present, severe erythema
Baseline, Week 12
Secondary Change From Baseline in Papule Lesions at Weeks 2, 4, 8, and 12 Papule - raised inflammatory lesions, <0.5 cm in diameter with no visible purulent material Baseline; Weeks 2, 4, 8, and 12
Secondary Change From Baseline in Pustule Lesions at Weeks 2, 4, 8, and 12 Pustule - raised inflammatory lesions, <0.5 cm in diameter with visible purulent material Baseline; Weeks 2, 4, 8, and 12
Secondary Change From Baseline in Nodule Lesions at Weeks 2, 4, 8, and 12 Nodule - any circumscribed, inflammatory mass =0.5 cm in diameter Baseline; Weeks 2, 4, 8, and 12
Secondary Change From Baseline in Papules + Pustules Lesions at Weeks 2, 4, 8, and 12 Papules + pustules lesions were the sum of counts of papule (raised inflammatory lesions, <0.5 cm in diameter with no visible purulent material) and pustule (raised inflammatory lesions, <0.5 cm in diameter with visible purulent material) lesions. Baseline; Weeks 2, 4, 8, and 12
Secondary Number of Participants With Adverse Events Number of participants reporting any adverse event including local tolerability of signs and symptoms of irritation, clinical laboratory safety tests, and vital signs. Baseline to Week 14
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05108025 - DMT310-005 Topical in the Treatment of Acne Rosacea Phase 2
Completed NCT02147691 - Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Phase 4
Completed NCT02270411 - Inflammatory Cells From Various Pathologies
Recruiting NCT04214483 - A Pilot Study to Explore the Role of Gut Flora in Acne
Completed NCT00041977 - Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea Phase 3
Completed NCT03003104 - DMT210 Topical Gel in the Treatment of Acne Rosacea Phase 2
Completed NCT00580723 - Effects of PRK 124 Lotion in Acne Rosacea Phase 1/Phase 2
Completed NCT04555525 - A Pilot Study on the Use of Seysara for Rosacea Phase 4